Conference Coverage

Switching from natalizumab to fingolimod or injectables increased MS disability

Publish date: June 1, 2014

 

AT THE CMSC/ACTRIMS ANNUAL MEETING

Dr. Cofield reported that she has received consulting fees from Teva Neuroscience and GlaxoSmithKline, among others. Biogen Idec funded the analysis of data for this study.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Pages

Recommended Reading

Functional Electrical Stimulation Cycling May Be Beneficial in Moderate to Severe MS
MDedge Neurology
iPad app could change how MS is measured, treated
MDedge Neurology
VIDEO: New MS database could change practice
MDedge Neurology
Clinical Characteristics Predictive of High Costs Among Patients With MS
MDedge Neurology
Attitudes Toward Exercise Correlate With Perceived Autonomy and Pain Among Patients With MS
MDedge Neurology
Improved outcomes seen with raising vitamin D levels in early MS
MDedge Neurology
Exercise is generally safe for MS patients
MDedge Neurology
VIDEO: Evidence backs marijuana for multiple sclerosis
MDedge Neurology
VIDEO: Tips for vaccinating multiple sclerosis patients
MDedge Neurology
VIDEO: How to talk to patients about MS drug risks
MDedge Neurology